The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its shortage list.

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

A group representing companies that made copycat versions of Eli Lilly & Co.’s weight-loss drugs sued the US Food and Drug Administration over the agency’s decision to remove Lilly’s medications from its shortage list.

A trade group representing compounding pharmacies sued the FDA for a “reckless and arbitrary” decision to remove Eli Lilly's tirzepatide from an official shortages list.

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) weight loss drug tirzepatide. Read more here.